文献速递前列腺癌

多西他赛失败后启动第二代内分泌治疗早期PSA下降预测转移性去势抵抗性前列腺癌的癌症特异性生存

Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2023-11-07

本回顾性研究纳入75例多西他赛治疗失败后接受阿比特龙或恩扎卢胺的转移性去势抵抗性前列腺癌患者,按治疗3个月内首次PSA下降幅度分为≥50%组(A组,52例)和<50%组(B组,23例)。中位随访30个月,A组中位影像学进展时间28.1个月 vs B组12.5个月(p=0.002)。多因素分析显示PSA下降≥50%与影像学进展风险降低(HR 0.41,95%CI 0.21-0.80,p=0.0113)及癌症特异性死亡风险降低(HR 0.29,95%CI 0.09-0.87,p=0.0325)显著相关。

要点

  • 多西他赛失败后启动第二代内分泌治疗3个月内PSA下降≥50%与影像学进展风险降低相关(HR 0.41)。
  • PSA下降≥50%与癌症特异性死亡风险降低相关(HR 0.29)。
  • A组中位影像学进展时间28.1个月 vs B组12.5个月(p=0.002)。

核心结论

  • 启动第二代内分泌治疗3个月内PSA下降≥50%与影像学无进展生存和3年癌症特异性死亡率显著改善相关。
  • 作者认为这提示可将PSA下降50%这一指标用于第二代内分泌治疗患者的监测,并识别需要进一步影像学评估的患者。

研究设计与样本

  • 回顾性研究,纳入75例多西他赛治疗失败(定义为PSA升高和影像学进展)后接受第二代内分泌治疗(阿比特龙或恩扎卢胺)的转移性去势抵抗性前列腺癌患者。
  • 根据治疗启动后3个月内首次PSA结果分为两组:PSA下降≥50%为A组(52例),PSA下降<50%为B组(23例)。
  • 主要终点为癌症特异性死亡率,次要终点为第二代内分泌治疗期间的影像学疾病进展。

主要发现

  • 中位随访时间为30个月,A组中位影像学疾病进展时间为28.1个月 vs B组12.5个月(p=0.002)。
  • 单因素和多因素分析显示,PSA下降≥50%与影像学疾病进展风险降低显著相关(HR 0.41,95%CI 0.21-0.80,p=0.0113)。
  • 单因素和多因素分析显示,PSA下降≥50%与癌症特异性死亡风险降低显著相关(HR 0.29,95%CI 0.09-0.87,p=0.0325)。
  • 转移性疾病体积也与影像学疾病进展风险降低及癌症特异性死亡风险降低显著相关。
  • 两组基线临床人口学特征(包括中位年龄、原发Gleason评分风险组、治疗前中位PSA、疾病负荷、转移部位和治疗前ECOG评分)无统计学差异。

临床怎么用

  • 作者认为,可将PSA下降50%这一指标用于接受第二代内分泌治疗患者的监测,并识别需要进一步影像学评估的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The objective of this study was to evaluate the prognostic value of early PSA decline following initiation of second-generation hormone therapy (2nd HT), namely abiraterone acetate or enzalutamide, in patients with taxane-refractory metastatic castrate-resistant prostate cancer (mCRPC) and evaluate utility of this metric in informing intensified surveillance/imaging protocols. METHODS: We retrospectively identified 75 mCRPC patients treated with 2nd HT following docetaxel failure (defined as PSA rise and radiographic progression). Patients were categorized patients into two cohorts based on the first PSA within 3 months after initiation of therapy: PSA reduction ≥50% (Group A) and PSA reduction <50% (Group B). The primary endpoint was cancer-specific mortality (CSM). The secondary endpoint was radiographic disease progression (rDP) on 2nd HT. In univariate and multivariate analyses, we investigated factors associated with rPD and CSM. RESULTS: We included 75 patients (52 in Group A, 23 in Group B) in the analytic cohort. Baseline clinico-demographic characteristics, including median age, primary Gleason score risk group, median pre-treatment PSA, disease burden, site of metastases, and pre-treatment ECOG score were not statistically different between the two groups. Median follow up time was 30 months and the median time to radiographic disease progression was 28.1 and 12.5 months (p = 0.002) in cohorts A and B, respectively. On univariate and multivariate analyses, both PSA reduction ≥50% and volume of metastatic disease were significantly associated with a decreased risk of radiographic disease progression (HR 0.41, 95% CI 0.21-0.80, p = 0.0113) as well as a decreased risk of cancer-specific mortality (HR 0.29, 95% CI 0.09-0.87, p = 0.0325). CONCLUSION: PSA reduction ≥50% within 3 months of starting 2nd HT was associated with significantly improved radiographic disease progression-free survival and 3-year cancer-specific mortality. This suggests using PSA 50%-decline metric in surveillance patients with on 2nd HT and identifies patients who require further evaluation with imaging.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Ahmed ME, Lee MS, Mahmoud AM, et al. Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2023. PMID: 37935879. doi:10.1038/s41391-023-00751-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。